Last reviewed · How we verify
Onartuzumab (MetMab)
Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling.
Onartuzumab is a monoclonal antibody that blocks hepatocyte growth factor (HGF) binding to the MET receptor, inhibiting MET-driven tumor growth and survival signaling. Used for Metastatic non-small cell lung cancer (NSCLC) in combination with erlotinib, Gastric cancer.
At a glance
| Generic name | Onartuzumab (MetMab) |
|---|---|
| Also known as | RO5490258 |
| Sponsor | Genentech, Inc. |
| Drug class | MET inhibitor monoclonal antibody |
| Target | MET (hepatocyte growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Onartuzumab acts as a one-armed antibody (half-antibody) that selectively binds to the extracellular domain of MET and prevents HGF from activating MET signaling. This blocks downstream pathways including PI3K/AKT and MAPK/ERK that promote cell proliferation, survival, and metastasis in MET-dependent cancers. By inhibiting HGF-MET interaction, the drug aims to overcome resistance mechanisms in tumors with elevated MET expression or activation.
Approved indications
- Metastatic non-small cell lung cancer (NSCLC) in combination with erlotinib
- Gastric cancer
Common side effects
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Rash
Key clinical trials
- An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study (PHASE3)
- A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma (PHASE2)
- FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer (PHASE2)
- A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib) (PHASE2)
- The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer (PHASE3)
- Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Onartuzumab (MetMab) CI brief — competitive landscape report
- Onartuzumab (MetMab) updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI